Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms
Open Access
- 31 March 2025
- journal article
- research article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e99
Abstract
Background: Findings from contemporary clinical trials suggest that psychedelics are generally safe and may be effective in the treatment of various psychiatric disorders. However, less is known about the risks associated with psychedelic use outside of medically supervised contexts, particularly in populations that are typically excluded from participation in clinical trials. Methods: Using a preregistered longitudinal observational research design with a purposive sample of US residents between 18 and 50 years old (N=21,990), we investigated associations between self-reported naturalistic psychedelic use and psychotic and manic symptoms, with emphasis on those with psychiatric histories of schizophrenia or bipolar I disorder. Results: The follow-up survey was completed by 12,345 participants (56% retention), with 505 participants reporting psychedelic use during the 2-month study period. In covariate-adjusted regression models, psychedelic use during the study period was associated with increases in the severity of psychotic and manic symptoms. However, such increases were only observed for those who reported psychedelic use in an illegal context. While increases in the severity of psychotic symptoms appeared to depend on the frequency of use and the intensity of challenging psychedelic experiences, increases in the severity of manic symptoms appeared to be moderated by a personal history of schizophrenia or bipolar I disorder and the subjective experience of insight during a psychedelic experience. Conclusions: The findings suggest that naturalistic psychedelic use specifically in illegal contexts may lead to increases in the severity of psychotic and manic symptoms. Such increases may depend on the frequency of use, the acute subjective psychedelic experience, and psychiatric history.Keywords
Funding Information
- Ekhagastiftelsen
This publication has 38 references indexed in Scilit:
- Psychedelic and MDMA-Related Adverse Effects—A Call for ActionJAMA Health Forum, 2024
- Adolescent Psychedelic Use and Psychotic or Manic SymptomsJAMA Psychiatry, 2024
- Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive EpisodesJAMA Psychiatry, 2024
- Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United KingdomJournal of Affective Disorders, 2024
- Use of Lysergic Acid Diethylamide by Major Depression StatusJAMA Psychiatry, 2024
- Single-Dose Psilocybin Treatment for Major Depressive DisorderJAMA, 2023
- Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelicsJournal of Affective Disorders, 2023
- Psychedelic Drug Legislative Reform and Legalization in the USJAMA Psychiatry, 2023
- The Current Status of Psychedelics in PsychiatryJAMA Psychiatry, 2021
- A Self-Report Scale to Help Make Psychiatric DiagnosesArchives of General Psychiatry, 2001